Rezon Bio

What Rezon Bio does

Rezon Bio is a Poland-headquartered European biologics contract development and manufacturing organization (CDMO) spun off from Polpharma Biologics in September 2025. The company operates two GMP-certified sites — a commercial-scale facility in Warsaw-Duchnice with 2,000L single-use bioreactor capacity (FDA-approved February 2026) and a clinical development and manufacturing center in Gdańsk — and provides end-to-end services spanning cell line development, upstream/downstream process development, analytical method development and qualification, technology transfer, MSAT, PPQ, GMP drug substance manufacturing, and quality and regulatory affairs support across 20+ markets. Rezon Bio serves biotech companies and small-to-mid-sized pharmaceutical firms developing biosimilars and novel biologics, with explicit positioning as a cost-competitive European alternative for clients seeking supply chain diversification away from China. The company is also targeting Asian biopharma clients through a dual-source manufacturing partnership with Chime Biologics.

The firm's underlying technology platform centers on mammalian cell culture production with single-use bioreactor infrastructure ranging from 50L to 2,000L, supplemented by Ambr high-throughput bioreactor systems, model-based digital twin simulations for line efficiency and yield, lean GMP workflows, smart scheduling, and Quality-by-Design/Design-of-Experiments-based process development. Rezon Bio holds FDA, EMA, MHRA, and ANVISA approvals and reports a 97% batch success rate since 2024 across 137 batches, with the workforce of >1,100 spanning 22 nationalities and including 80% higher-education degree holders and 10% PhDs.

The company generates revenue primarily through project-based contracts for development and manufacturing services, with three published pricing models — campaign-based (fixed capacity per batch), gram-based (output-aligned), and shared-capacity (hybrid) — targeting biotech and pharma clients via direct enterprise sales, conference-led engagement (BIO International, Dutch Biotech Event, European Economic Congress), and a dedicated meeting-scheduling platform. Legacy clients include Sandoz and Teva, and the firm is backed by Jerzy Starak of the Polpharma Group.

Name

Rezon Bio

Legal name

Polpharma Biologics SA

Website

https://rezonbio.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Rezon Bio is a European biologics CDMO operating two GMP-certified Polish facilities, offering end-to-end cell line development, process development, and clinical-to-commercial GMP manufacturing services for biotech and pharma companies developing biosimilars and novel biologics.

Ownership category

akta.pro rank

Product category

Biologics CDMO Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

Keywords

• Biologics CDMO services
• Contract development manufacturing
• GMP biopharmaceutical manufacturing
• Biosimilar development services
• Mammalian cell culture production

Headquarters

HQ city

Duchnice

HQ country

Poland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Contract Development and Manufacturing Services: Full-service CDMO providing end-to-end biologics development and manufacturing services from cell line development through commercial GMP manufacturing. Revenue generated through project-based contracts with transparent milestone-based pricing.
2. GMP Manufacturing Services: Clinical and commercial-scale GMP manufacturing capacity with flexible pricing models including campaign-based, gram-based or shared capacity options. Multiple pricing structures to accommodate different client needs and program scales.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

Rezon Bio is a European biologics Contract Development and Manufacturing Organization (CDMO) providing end-to-end development and manufacturing services for biologics and biosimilars across two GMP-certified sites in Poland (Warsaw-Duchnice and Gdańsk). Services span cell line development, upstream and downstream process development, analytical method development, GMP drug substance manufacturing using single-use bioreactors (50L–2,000L), technology transfer, MSAT, PPQ, and global regulatory affairs for biotech and pharmaceutical clients.

Product overview

Rezon Bio is a European biologics CDMO offering cost-efficient, scalable solutions for biologics programs through an integrated, end-to-end platform spanning two GMP-certified sites in Poland (Warsaw-Duchnice and Gdańsk). The platform comprises five interconnected service modules: Process Development & Characterization Services (for scalable upstream/downstream process development from lab to commercial scale), Analytical Capabilities (phase-appropriate testing for quality and release), GMP Manufacturing (clinical and commercial-scale single-use bioreactor capacity approved by FDA and EMA), Quality & Regulatory Affairs (global regulatory compliance and QA oversight across 20+ markets), and Technology Transfer, MSAT & PPQ (seamless tech transfer and process qualification services). These services work together to deliver integrated solutions from cell line development through commercial supply, with a unified quality system across both facilities.

Differentiator

Problem solved

Functional benefit

Products and services

• Process Development & Characterization Services Scalable upstream and downstream biologics processes built for robustness, optimized for biosimilars and new biological entities (NBEs) from lab to commercial scale, including cell line development, upstream/downstream development, and DoE-driven process characterization.
• Analytical Capabilities Phase-appropriate, method-qualified testing for product quality and release, including method development, qualification and validation, potency testing (ELISA, SPR/BLI, cell-based), stability studies, release testing (sterility, endotoxin, bioburden, mycoplasma), and CMC filing support.
• GMP Manufacturing Flexible single-use GMP capacity at clinical and commercial scale, inspection-ready and approved by FDA and EMA. Services include drug substance manufacturing, scalable bioreactor capacity (50L-2000L), and lean GMP workflows with digital optimization.
• Quality & Regulatory Affairs Global regulatory compliance and quality assurance built into every biologics process, including QA oversight from development to commercial, regulatory submissions across 20+ markets, batch record design, deviation management, and inspection readiness planning for EMA, FDA, ANVISA, and MHRA.
• Technology Transfer, MSAT & PPQ Integrated biologics tech transfer, MSAT, and PPQ solutions including internal and external tech transfers, process mapping and optimization, analytical method review and bridging, on-scale engineering runs, regulatory support, and PPQ preparation and execution for seamless GMP readiness.

Quantifiable outcome

• 97% batch success rate since 2024
• +9 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Four partnerships are on record, tiered core, major and minor.

• Chime BiologicscoreStrategic or Co-development Partner · 24 June 2026Collaboration to offer geographically diversified dual-source manufacturing strategy spanning Europe and Asia. Enables clients to build resilient supply strategies without operational complexity through single point of contact, seamless technology transfer, and unified project governance. Provides US and European companies access to cost-efficient Asian manufacturing while providing Asian companies access to European regulatory expertise and FDA/EMA compliant manufacturing.
• SandozmajorStrategic or Co-development PartnerExisting partnership with Sandoz for biologics manufacturing services as part of Rezon Bio's legacy client relationships from Polpharma Biologics.
• TevamajorStrategic or Co-development PartnerExisting partnership with Teva for biologics manufacturing services as part of Rezon Bio's legacy client relationships from Polpharma Biologics.
• Warsaw University of Life Sciences (SGGW)minorStrategic or Co-development PartnerCollaboration on BioFuture Challenge competition offering fully funded postgraduate program in Pharmaceutical Biotechnology. Joint initiative combining academic expertise with industry perspective on biologics development and manufacturing.

Scale indicators18 records

Recent moves10 records

Expansion highlights6 records

Broad incumbents

• Samsung Biologics: Samsung Biologics is the world's largest mammalian cell culture CDMO by capacity, offering end-to-end biologics development and manufacturing services from clinical to commercial scale. Direct comparison to Rezon Bio as a biologics CDMO targeting biosimilar and novel biologic clients, though substantially larger in installed capacity and breadth of services.
• Lonza: Lonza is one of the largest global CDMOs with extensive mammalian and microbial biologics manufacturing capacity across multiple sites worldwide. Direct overlap with Rezon Bio in mammalian cell culture CDMO services for biosimilars and novel biologics, though at materially greater scale and with broader service breadth including cell and gene therapy.
• Catalent (Novo Holdings): Catalent is a major global CDMO offering biologics, cell and gene therapy, and fill-finish services, recently acquired by Novo Holdings for $16.5B. Direct overlap with Rezon Bio in biologics CDMO services, though substantially larger and broader in service portfolio and geographic reach.
• WuXi Biologics: WuXi Biologics is the largest China-based biologics CDMO with extensive global capacity for mammalian cell culture manufacturing. Rezon Bio is explicitly positioning as a European alternative to WuXi Biologics under EU reshoring dynamics, making it the primary competitive foil Rezon Bio is targeting for displaced demand.

Direct peers

• Boehringer Ingelheim BioXcellence: Boehringer Ingelheim BioXcellence is a global biologics CDMO offering mammalian cell culture-based contract manufacturing services from cell line development through commercial supply. Highly comparable to Rezon Bio in service model, target customers (biotech and pharma biosimilar developers), and mammalian biologics focus. Notably, Rezon Bio's COO Dr. Ralf Otto previously held senior leadership at this organization.
• Rentschler Biopharma: Rentschler Biopharma is a German-based family-owned CDMO specializing in mammalian cell culture biologics manufacturing for clinical and commercial supply. Highly comparable mid-sized European CDMO peer to Rezon Bio, with similar positioning as a quality-focused, science-driven alternative to mega-CDMOs. Rezon Bio's COO Dr. Ralf Otto served as President and CEO of Rentschler Biopharma before joining Rezon Bio.
• AGC Biologics: AGC Biologics is a global CDMO offering mammalian and microbial biologics manufacturing, with facilities in the US, Europe, and Asia. Closely comparable to Rezon Bio in service scope (process development through commercial manufacturing) and target customer base (biotech and pharma developing biologics and biosimilars).
• Chime Biologics: Chime Biologics is an Asia-based biologics CDMO with GMP manufacturing capacity. Rezon Bio's June 2026 strategic dual-source manufacturing partnership with Chime Biologics makes them both partners and the most direct comparable peer in geographic positioning (Asia vs. Europe), service scope, and target customer base.
• IDT Biologika: IDT Biologika is a German CDMO offering biologics fill-finish and manufacturing services for vaccines and biopharmaceuticals. Comparable European mid-sized CDMO peer to Rezon Bio, with similar positioning as a quality-focused alternative to mega-CDMOs and target customers in biotech and biosimilar developers.

Others

• Polpharma Biologics: Polpharma Biologics is the parent organization from which Rezon Bio was spun off in September 2025. While not a direct competitor, Polpharma Biologics shares the biologics manufacturing DNA, customer relationships (Sandoz, Teva), and 16-year heritage that define Rezon Bio's positioning, making it the closest corporate comparable in terms of operating model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/rezonbio

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rezon Bio